Arcadia Biosciences Inc (RKDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has a cash flow conversion efficiency ratio of -0.047x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-257.00K) by net assets ($5.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arcadia Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Arcadia Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read RKDA current and long-term liabilities for a breakdown of total debt and financial obligations.
Arcadia Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcadia Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Savannah Resources Plc
LSE:SAV
|
-0.052x |
|
DigiAsia Corp
NASDAQ:FAAS
|
-0.018x |
|
Volato Group Inc.
NYSE:SOAR
|
-0.120x |
|
Volato Group Inc.
NYSE MKT:SOAR
|
-0.705x |
|
Lambo Group Bhd
KLSE:0018
|
-0.022x |
|
Grosvenor Resource Corp
V:GVR
|
-0.078x |
|
Black Hawk Acquisition Corporation Rights
NASDAQ:BKHAR
|
N/A |
|
Savannah Energy PLC
LSE:SAVE
|
0.060x |
Annual Cash Flow Conversion Efficiency for Arcadia Biosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Arcadia Biosciences Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Arcadia Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.22 Million | $-9.63 Million | -1.547x | -28.49% |
| 2023-12-31 | $12.70 Million | $-15.29 Million | -1.204x | -80.03% |
| 2022-12-31 | $20.90 Million | $-13.98 Million | -0.669x | +19.35% |
| 2021-12-31 | $31.20 Million | $-25.87 Million | -0.829x | +21.65% |
| 2020-12-31 | $28.55 Million | $-30.22 Million | -1.058x | +48.76% |
| 2019-12-31 | $8.33 Million | $-17.20 Million | -2.066x | -94.19% |
| 2018-12-31 | $12.81 Million | $-13.63 Million | -1.064x | +39.01% |
| 2017-12-31 | $8.01 Million | $-13.96 Million | -1.744x | -127.00% |
| 2016-12-31 | $22.20 Million | $-17.05 Million | -0.768x | -104.55% |
| 2015-12-31 | $40.23 Million | $-15.11 Million | -0.376x | -104.79% |
| 2014-12-31 | $-1.89 Million | $-14.79 Million | 7.845x | +1292.38% |
| 2013-12-31 | $-17.30 Million | $-9.74 Million | 0.563x | -66.60% |
| 2012-12-31 | $-5.68 Million | $-9.59 Million | 1.687x | -- |
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more